| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 523 | 2024 | 11835 | 21.540 |
Why?
|
| Stroke Volume | 219 | 2024 | 5513 | 8.500 |
Why?
|
| Natriuretic Peptide, Brain | 90 | 2024 | 1705 | 6.580 |
Why?
|
| Registries | 159 | 2022 | 8449 | 5.610 |
Why?
|
| Hospitalization | 186 | 2024 | 10761 | 5.510 |
Why?
|
| Patient Readmission | 90 | 2023 | 3327 | 4.950 |
Why?
|
| Natriuretic Agents | 33 | 2021 | 57 | 4.320 |
Why?
|
| Guideline Adherence | 76 | 2020 | 2283 | 3.850 |
Why?
|
| Ventricular Dysfunction, Left | 39 | 2024 | 2129 | 3.280 |
Why?
|
| Glucosides | 27 | 2024 | 536 | 3.270 |
Why?
|
| Patient Discharge | 67 | 2023 | 3475 | 3.160 |
Why?
|
| Ventricular Function, Left | 78 | 2024 | 3870 | 3.120 |
Why?
|
| Benzhydryl Compounds | 33 | 2024 | 942 | 3.040 |
Why?
|
| Defibrillators, Implantable | 33 | 2022 | 1499 | 2.960 |
Why?
|
| Angiotensin Receptor Antagonists | 38 | 2024 | 1025 | 2.880 |
Why?
|
| Stroke | 89 | 2024 | 9945 | 2.820 |
Why?
|
| Medicare | 88 | 2024 | 6771 | 2.810 |
Why?
|
| Myocardial Infarction | 64 | 2024 | 11891 | 2.710 |
Why?
|
| Practice Guidelines as Topic | 92 | 2021 | 7468 | 2.670 |
Why?
|
| Quality of Health Care | 60 | 2021 | 4361 | 2.590 |
Why?
|
| Aged | 501 | 2024 | 168995 | 2.570 |
Why?
|
| Cardiovascular Diseases | 65 | 2024 | 15740 | 2.570 |
Why?
|
| Tetrazoles | 23 | 2024 | 901 | 2.550 |
Why?
|
| Adrenergic beta-Antagonists | 24 | 2023 | 1256 | 2.510 |
Why?
|
| Heterocyclic Compounds, 2-Ring | 16 | 2024 | 38 | 2.440 |
Why?
|
| Diuretics | 24 | 2023 | 612 | 2.420 |
Why?
|
| Hospital Mortality | 89 | 2023 | 5420 | 2.400 |
Why?
|
| Diabetes Mellitus, Type 2 | 54 | 2024 | 12281 | 2.310 |
Why?
|
| Heart-Assist Devices | 20 | 2020 | 1290 | 2.310 |
Why?
|
| Brain Ischemia | 39 | 2023 | 3127 | 2.130 |
Why?
|
| Humans | 837 | 2024 | 760261 | 2.100 |
Why?
|
| Atrial Fibrillation | 43 | 2023 | 5201 | 2.070 |
Why?
|
| Tissue Plasminogen Activator | 25 | 2022 | 1190 | 2.030 |
Why?
|
| Aged, 80 and over | 238 | 2023 | 58947 | 2.010 |
Why?
|
| Hospitals | 36 | 2021 | 3929 | 2.000 |
Why?
|
| United States | 284 | 2024 | 72363 | 1.970 |
Why?
|
| Cardiovascular Agents | 16 | 2020 | 864 | 1.970 |
Why?
|
| Acute Disease | 92 | 2021 | 7268 | 1.960 |
Why?
|
| Treatment Outcome | 232 | 2024 | 64947 | 1.950 |
Why?
|
| Neprilysin | 18 | 2023 | 472 | 1.930 |
Why?
|
| Male | 537 | 2024 | 359413 | 1.900 |
Why?
|
| Cardiac Resynchronization Therapy | 14 | 2022 | 556 | 1.880 |
Why?
|
| Anticoagulants | 42 | 2023 | 4896 | 1.860 |
Why?
|
| Quality Improvement | 32 | 2021 | 3840 | 1.830 |
Why?
|
| Female | 530 | 2024 | 391011 | 1.770 |
Why?
|
| Cardiovascular System | 10 | 2023 | 850 | 1.760 |
Why?
|
| American Heart Association | 39 | 2024 | 1081 | 1.740 |
Why?
|
| Aftercare | 15 | 2023 | 918 | 1.680 |
Why?
|
| Warfarin | 16 | 2018 | 1516 | 1.630 |
Why?
|
| Hypoglycemic Agents | 27 | 2024 | 3149 | 1.610 |
Why?
|
| Dyspnea | 24 | 2023 | 1352 | 1.570 |
Why?
|
| Clinical Trials as Topic | 29 | 2024 | 8058 | 1.560 |
Why?
|
| Benzamides | 17 | 2019 | 1369 | 1.490 |
Why?
|
| Double-Blind Method | 77 | 2024 | 12412 | 1.450 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 28 | 2024 | 1521 | 1.430 |
Why?
|
| Middle Aged | 345 | 2024 | 220175 | 1.430 |
Why?
|
| Cardiology | 20 | 2023 | 1723 | 1.430 |
Why?
|
| Enoxaparin | 16 | 2022 | 397 | 1.410 |
Why?
|
| Time Factors | 122 | 2024 | 40133 | 1.400 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 10 | 2023 | 150 | 1.400 |
Why?
|
| Secondary Prevention | 15 | 2024 | 1548 | 1.400 |
Why?
|
| Fibrinolytic Agents | 24 | 2023 | 2167 | 1.390 |
Why?
|
| Randomized Controlled Trials as Topic | 56 | 2024 | 10340 | 1.390 |
Why?
|
| Research Design | 33 | 2024 | 6181 | 1.350 |
Why?
|
| Glucagon-Like Peptide 1 | 7 | 2024 | 366 | 1.350 |
Why?
|
| Cardiotonic Agents | 12 | 2021 | 546 | 1.340 |
Why?
|
| Risk Assessment | 91 | 2024 | 24086 | 1.340 |
Why?
|
| Maltose | 3 | 2024 | 39 | 1.330 |
Why?
|
| Inpatients | 28 | 2023 | 2578 | 1.290 |
Why?
|
| Vasodilator Agents | 10 | 2018 | 977 | 1.290 |
Why?
|
| Aspirin | 22 | 2024 | 3365 | 1.280 |
Why?
|
| Electronic Health Records | 18 | 2022 | 4763 | 1.270 |
Why?
|
| Glomerular Filtration Rate | 24 | 2024 | 2178 | 1.260 |
Why?
|
| Heart Failure, Systolic | 5 | 2023 | 136 | 1.230 |
Why?
|
| Renal Insufficiency, Chronic | 13 | 2024 | 2296 | 1.220 |
Why?
|
| Peptide Fragments | 38 | 2024 | 5120 | 1.220 |
Why?
|
| Biphenyl Compounds | 23 | 2024 | 988 | 1.190 |
Why?
|
| Biomedical Research | 14 | 2021 | 3421 | 1.170 |
Why?
|
| Renal Insufficiency | 14 | 2019 | 820 | 1.160 |
Why?
|
| Pyridines | 20 | 2019 | 2877 | 1.120 |
Why?
|
| Venous Thromboembolism | 20 | 2022 | 1866 | 1.120 |
Why?
|
| Length of Stay | 40 | 2022 | 6472 | 1.110 |
Why?
|
| Cause of Death | 35 | 2024 | 3723 | 1.110 |
Why?
|
| Heart Rate | 13 | 2023 | 4169 | 1.100 |
Why?
|
| Acute Coronary Syndrome | 16 | 2023 | 2362 | 1.050 |
Why?
|
| Delivery of Health Care | 15 | 2024 | 5324 | 1.030 |
Why?
|
| Drug Combinations | 25 | 2024 | 2024 | 1.030 |
Why?
|
| Quality of Life | 40 | 2024 | 13300 | 1.020 |
Why?
|
| Proportional Hazards Models | 52 | 2024 | 12532 | 1.020 |
Why?
|
| Ferric Compounds | 6 | 2024 | 378 | 1.000 |
Why?
|
| Follow-Up Studies | 81 | 2024 | 39254 | 0.980 |
Why?
|
| Quality Indicators, Health Care | 17 | 2021 | 1822 | 0.970 |
Why?
|
| Prognosis | 76 | 2024 | 29636 | 0.960 |
Why?
|
| Evidence-Based Medicine | 22 | 2024 | 3696 | 0.950 |
Why?
|
| Survival Rate | 59 | 2021 | 12806 | 0.950 |
Why?
|
| Risk Factors | 141 | 2024 | 74269 | 0.940 |
Why?
|
| Survival Analysis | 40 | 2021 | 10185 | 0.930 |
Why?
|
| Hypotension | 8 | 2023 | 883 | 0.930 |
Why?
|
| Creatinine | 13 | 2021 | 1906 | 0.920 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 10 | 2023 | 3333 | 0.920 |
Why?
|
| Relaxin | 4 | 2014 | 42 | 0.910 |
Why?
|
| Protease Inhibitors | 5 | 2021 | 755 | 0.900 |
Why?
|
| Disease Management | 14 | 2019 | 2508 | 0.890 |
Why?
|
| Pyrimidines | 15 | 2024 | 3011 | 0.880 |
Why?
|
| Death, Sudden, Cardiac | 16 | 2020 | 1572 | 0.880 |
Why?
|
| Furosemide | 9 | 2023 | 170 | 0.880 |
Why?
|
| Heart Failure, Diastolic | 5 | 2024 | 77 | 0.870 |
Why?
|
| Platelet Aggregation Inhibitors | 19 | 2024 | 3201 | 0.850 |
Why?
|
| Diabetes Mellitus | 17 | 2024 | 5884 | 0.850 |
Why?
|
| Comorbidity | 40 | 2023 | 10552 | 0.840 |
Why?
|
| Retrospective Studies | 129 | 2023 | 80301 | 0.830 |
Why?
|
| Ambulatory Care | 11 | 2023 | 2783 | 0.830 |
Why?
|
| Disease Progression | 36 | 2024 | 13505 | 0.830 |
Why?
|
| Hyperkalemia | 6 | 2022 | 231 | 0.820 |
Why?
|
| Hydralazine | 3 | 2019 | 36 | 0.820 |
Why?
|
| Patient Admission | 12 | 2020 | 1384 | 0.820 |
Why?
|
| Ischemic Attack, Transient | 5 | 2015 | 899 | 0.810 |
Why?
|
| Thrombolytic Therapy | 14 | 2021 | 2108 | 0.810 |
Why?
|
| Insurance Benefits | 2 | 2016 | 191 | 0.810 |
Why?
|
| Influenza Vaccines | 6 | 2022 | 770 | 0.790 |
Why?
|
| Exercise Tolerance | 13 | 2020 | 826 | 0.790 |
Why?
|
| Venoms | 3 | 2017 | 96 | 0.790 |
Why?
|
| Information Dissemination | 7 | 2020 | 1132 | 0.790 |
Why?
|
| Mortality | 13 | 2021 | 2916 | 0.780 |
Why?
|
| Spironolactone | 7 | 2020 | 411 | 0.780 |
Why?
|
| Patient-Centered Care | 6 | 2023 | 1416 | 0.750 |
Why?
|
| Dose-Response Relationship, Drug | 34 | 2024 | 10829 | 0.750 |
Why?
|
| Ultrafiltration | 4 | 2020 | 49 | 0.750 |
Why?
|
| Amiodarone | 5 | 2018 | 218 | 0.750 |
Why?
|
| Kidney | 20 | 2023 | 7072 | 0.750 |
Why?
|
| Healthcare Disparities | 21 | 2018 | 3381 | 0.740 |
Why?
|
| Coronary Artery Disease | 24 | 2022 | 6661 | 0.740 |
Why?
|
| Medicare Part D | 5 | 2018 | 354 | 0.740 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 8 | 2021 | 435 | 0.730 |
Why?
|
| Incretins | 6 | 2024 | 103 | 0.730 |
Why?
|
| Splanchnic Nerves | 7 | 2023 | 16 | 0.720 |
Why?
|
| Multivariate Analysis | 39 | 2019 | 12156 | 0.710 |
Why?
|
| Patient Selection | 21 | 2020 | 4276 | 0.710 |
Why?
|
| Cardiomyopathies | 9 | 2023 | 1945 | 0.700 |
Why?
|
| Anemia, Iron-Deficiency | 5 | 2024 | 368 | 0.690 |
Why?
|
| Health Care Costs | 10 | 2020 | 3257 | 0.680 |
Why?
|
| Cardiac Pacing, Artificial | 4 | 2018 | 865 | 0.670 |
Why?
|
| Kaplan-Meier Estimate | 26 | 2024 | 6545 | 0.670 |
Why?
|
| Renin-Angiotensin System | 8 | 2021 | 739 | 0.670 |
Why?
|
| Primary Prevention | 13 | 2020 | 1207 | 0.670 |
Why?
|
| Logistic Models | 37 | 2018 | 13311 | 0.670 |
Why?
|
| Chi-Square Distribution | 25 | 2018 | 3466 | 0.650 |
Why?
|
| Isosorbide Dinitrate | 2 | 2016 | 37 | 0.640 |
Why?
|
| Multicenter Studies as Topic | 12 | 2022 | 1723 | 0.640 |
Why?
|
| Heart Diseases | 7 | 2020 | 2809 | 0.640 |
Why?
|
| Electric Countershock | 8 | 2016 | 537 | 0.630 |
Why?
|
| Intra-Aortic Balloon Pumping | 2 | 2018 | 227 | 0.620 |
Why?
|
| Diuresis | 3 | 2018 | 107 | 0.620 |
Why?
|
| Information Storage and Retrieval | 5 | 2020 | 821 | 0.610 |
Why?
|
| Happiness | 1 | 2019 | 170 | 0.600 |
Why?
|
| Drug Administration Schedule | 21 | 2021 | 4900 | 0.600 |
Why?
|
| Pneumococcal Vaccines | 2 | 2018 | 397 | 0.580 |
Why?
|
| Evidence-Based Practice | 4 | 2020 | 495 | 0.580 |
Why?
|
| Pacemaker, Artificial | 4 | 2018 | 815 | 0.580 |
Why?
|
| Intracranial Hemorrhages | 9 | 2023 | 844 | 0.580 |
Why?
|
| Odds Ratio | 31 | 2018 | 9712 | 0.570 |
Why?
|
| Peripheral Arterial Disease | 8 | 2024 | 1305 | 0.560 |
Why?
|
| Guidelines as Topic | 9 | 2017 | 1395 | 0.550 |
Why?
|
| Bilirubin | 2 | 2015 | 438 | 0.550 |
Why?
|
| Digoxin | 2 | 2016 | 247 | 0.540 |
Why?
|
| Hemorrhage | 19 | 2024 | 3604 | 0.540 |
Why?
|
| Drug Utilization | 15 | 2019 | 1195 | 0.540 |
Why?
|
| Kidney Diseases | 10 | 2023 | 2093 | 0.540 |
Why?
|
| Health Resources | 7 | 2019 | 936 | 0.540 |
Why?
|
| Medication Adherence | 8 | 2021 | 2163 | 0.540 |
Why?
|
| Respiration Disorders | 1 | 2019 | 368 | 0.530 |
Why?
|
| Insurance Claim Reporting | 2 | 2016 | 165 | 0.520 |
Why?
|
| Heart Transplantation | 16 | 2020 | 3217 | 0.520 |
Why?
|
| Incidence | 40 | 2023 | 21378 | 0.520 |
Why?
|
| Research Report | 8 | 2022 | 370 | 0.520 |
Why?
|
| Troponin | 2 | 2017 | 516 | 0.520 |
Why?
|
| Atherosclerosis | 9 | 2024 | 3524 | 0.520 |
Why?
|
| Insurance Claim Review | 5 | 2018 | 737 | 0.510 |
Why?
|
| Amino Acid Metabolism, Inborn Errors | 1 | 2018 | 282 | 0.510 |
Why?
|
| Anti-Arrhythmia Agents | 6 | 2019 | 784 | 0.510 |
Why?
|
| Community Networks | 1 | 2017 | 201 | 0.500 |
Why?
|
| Severity of Illness Index | 37 | 2022 | 15827 | 0.500 |
Why?
|
| Age Factors | 44 | 2020 | 18415 | 0.500 |
Why?
|
| Transportation of Patients | 2 | 2015 | 176 | 0.500 |
Why?
|
| Diabetes Complications | 5 | 2020 | 1342 | 0.490 |
Why?
|
| Coronary Artery Bypass | 9 | 2014 | 2273 | 0.490 |
Why?
|
| Prospective Studies | 59 | 2024 | 54263 | 0.490 |
Why?
|
| Equipment Failure | 3 | 2013 | 577 | 0.480 |
Why?
|
| Venous Thrombosis | 9 | 2022 | 1293 | 0.470 |
Why?
|
| Endpoint Determination | 8 | 2019 | 597 | 0.470 |
Why?
|
| Diabetic Angiopathies | 6 | 2019 | 822 | 0.470 |
Why?
|
| Databases, Factual | 16 | 2020 | 8018 | 0.470 |
Why?
|
| Aspartate Aminotransferases | 1 | 2015 | 415 | 0.470 |
Why?
|
| Interinstitutional Relations | 1 | 2015 | 238 | 0.470 |
Why?
|
| Quality Assurance, Health Care | 11 | 2015 | 2178 | 0.470 |
Why?
|
| Recovery of Function | 14 | 2022 | 2982 | 0.460 |
Why?
|
| Blood Pressure | 15 | 2023 | 8523 | 0.460 |
Why?
|
| Cohort Studies | 50 | 2021 | 41317 | 0.450 |
Why?
|
| Telemedicine | 6 | 2024 | 3005 | 0.450 |
Why?
|
| Computer Communication Networks | 1 | 2015 | 294 | 0.440 |
Why?
|
| Injections, Intravenous | 9 | 2021 | 1388 | 0.440 |
Why?
|
| Iron Compounds | 3 | 2019 | 28 | 0.440 |
Why?
|
| Administration, Oral | 16 | 2023 | 4044 | 0.440 |
Why?
|
| Edema | 7 | 2020 | 772 | 0.440 |
Why?
|
| Addison Disease | 1 | 2013 | 48 | 0.440 |
Why?
|
| Receptors, Adrenergic, beta-1 | 1 | 2013 | 51 | 0.440 |
Why?
|
| Patient Care Team | 3 | 2015 | 2510 | 0.440 |
Why?
|
| Emergency Service, Hospital | 12 | 2019 | 7809 | 0.430 |
Why?
|
| Alanine Transaminase | 1 | 2015 | 607 | 0.430 |
Why?
|
| Population Groups | 1 | 2014 | 211 | 0.420 |
Why?
|
| Hospital Costs | 3 | 2019 | 976 | 0.420 |
Why?
|
| Drug Prescriptions | 8 | 2019 | 1673 | 0.410 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 4 | 2014 | 103 | 0.410 |
Why?
|
| Infusions, Intravenous | 12 | 2021 | 2235 | 0.410 |
Why?
|
| Comparative Effectiveness Research | 7 | 2020 | 718 | 0.410 |
Why?
|
| Angioplasty, Balloon, Coronary | 7 | 2012 | 1880 | 0.410 |
Why?
|
| Societies, Medical | 10 | 2019 | 3903 | 0.410 |
Why?
|
| Research Subjects | 3 | 2018 | 249 | 0.410 |
Why?
|
| Appointments and Schedules | 1 | 2016 | 443 | 0.390 |
Why?
|
| Cardiac Imaging Techniques | 3 | 2018 | 269 | 0.390 |
Why?
|
| Models, Theoretical | 3 | 2013 | 3561 | 0.390 |
Why?
|
| Feedback | 1 | 2015 | 791 | 0.380 |
Why?
|
| Monitoring, Ambulatory | 1 | 2014 | 353 | 0.380 |
Why?
|
| Influenza, Human | 5 | 2022 | 1532 | 0.380 |
Why?
|
| Heart Conduction System | 2 | 2014 | 1016 | 0.380 |
Why?
|
| Myocardial Revascularization | 7 | 2021 | 841 | 0.370 |
Why?
|
| Propensity Score | 10 | 2020 | 1918 | 0.370 |
Why?
|
| Patient Preference | 2 | 2016 | 921 | 0.370 |
Why?
|
| Sex Factors | 23 | 2024 | 10530 | 0.370 |
Why?
|
| Triglycerides | 2 | 2018 | 2476 | 0.370 |
Why?
|
| National Institutes of Health (U.S.) | 5 | 2023 | 787 | 0.370 |
Why?
|
| Vasoconstrictor Agents | 3 | 2022 | 651 | 0.370 |
Why?
|
| Latin America | 5 | 2016 | 405 | 0.370 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 1 | 2010 | 78 | 0.360 |
Why?
|
| Angina Pectoris | 1 | 2014 | 969 | 0.360 |
Why?
|
| Forecasting | 7 | 2024 | 2931 | 0.360 |
Why?
|
| Cerebral Hemorrhage | 8 | 2018 | 2660 | 0.360 |
Why?
|
| Hospitals, Teaching | 4 | 2016 | 1166 | 0.350 |
Why?
|
| Vaccination | 3 | 2022 | 3360 | 0.350 |
Why?
|
| Health Status | 14 | 2023 | 4081 | 0.350 |
Why?
|
| Risk | 16 | 2019 | 9629 | 0.350 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2015 | 464 | 0.350 |
Why?
|
| Surgical Procedures, Operative | 3 | 2008 | 1919 | 0.350 |
Why?
|
| Cost Savings | 1 | 2015 | 920 | 0.350 |
Why?
|
| Peptides | 3 | 2017 | 4358 | 0.350 |
Why?
|
| Hemodynamics | 10 | 2022 | 4169 | 0.340 |
Why?
|
| Oxygen Consumption | 10 | 2020 | 1840 | 0.340 |
Why?
|
| Cost of Illness | 4 | 2024 | 1940 | 0.340 |
Why?
|
| Uncertainty | 1 | 2014 | 754 | 0.340 |
Why?
|
| Adenosine A1 Receptor Agonists | 2 | 2019 | 13 | 0.330 |
Why?
|
| Hospitalists | 1 | 2013 | 295 | 0.330 |
Why?
|
| Health Status Disparities | 5 | 2018 | 1819 | 0.330 |
Why?
|
| Injections, Subcutaneous | 4 | 2018 | 679 | 0.320 |
Why?
|
| Health Services | 1 | 2014 | 754 | 0.320 |
Why?
|
| Health Behavior | 3 | 2017 | 2621 | 0.320 |
Why?
|
| Predictive Value of Tests | 24 | 2021 | 15273 | 0.320 |
Why?
|
| Valine | 2 | 2013 | 409 | 0.320 |
Why?
|
| Troponin I | 4 | 2018 | 634 | 0.320 |
Why?
|
| Ventricular Dysfunction | 2 | 2014 | 145 | 0.320 |
Why?
|
| Ethics Committees, Research | 2 | 2021 | 197 | 0.310 |
Why?
|
| Exercise Test | 11 | 2020 | 2125 | 0.310 |
Why?
|
| Data Collection | 5 | 2019 | 3317 | 0.310 |
Why?
|
| Vitamin K | 2 | 2023 | 321 | 0.310 |
Why?
|
| Heart Valve Prosthesis Implantation | 6 | 2021 | 1583 | 0.310 |
Why?
|
| Thromboembolism | 3 | 2013 | 1016 | 0.310 |
Why?
|
| Decision Support Techniques | 3 | 2015 | 2002 | 0.300 |
Why?
|
| Medicaid | 6 | 2018 | 2811 | 0.300 |
Why?
|
| Self Care | 3 | 2019 | 793 | 0.300 |
Why?
|
| Autonomic Nerve Block | 2 | 2018 | 81 | 0.300 |
Why?
|
| Hepacivirus | 1 | 2015 | 1333 | 0.300 |
Why?
|
| Terminal Care | 2 | 2018 | 1759 | 0.300 |
Why?
|
| Metformin | 3 | 2021 | 912 | 0.300 |
Why?
|
| Ramipril | 1 | 2008 | 97 | 0.300 |
Why?
|
| Aldosterone | 6 | 2021 | 868 | 0.300 |
Why?
|
| Activities of Daily Living | 5 | 2023 | 2414 | 0.290 |
Why?
|
| Emergency Medical Services | 7 | 2016 | 1927 | 0.290 |
Why?
|
| Socioeconomic Factors | 5 | 2020 | 7803 | 0.290 |
Why?
|
| Shock, Cardiogenic | 1 | 2013 | 734 | 0.290 |
Why?
|
| Perioperative Care | 3 | 2011 | 1032 | 0.290 |
Why?
|
| Sulfones | 4 | 2014 | 447 | 0.290 |
Why?
|
| Palliative Care | 3 | 2018 | 3607 | 0.290 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2013 | 819 | 0.280 |
Why?
|
| Adult | 66 | 2024 | 219847 | 0.280 |
Why?
|
| Ankle Brachial Index | 3 | 2024 | 163 | 0.280 |
Why?
|
| Hepatitis C, Chronic | 1 | 2015 | 1031 | 0.280 |
Why?
|
| Chronic Disease | 14 | 2023 | 9283 | 0.280 |
Why?
|
| Dipeptides | 2 | 2019 | 410 | 0.280 |
Why?
|
| Risk Reduction Behavior | 2 | 2012 | 1109 | 0.280 |
Why?
|
| Cystatin C | 6 | 2023 | 270 | 0.270 |
Why?
|
| Pneumonia, Pneumococcal | 2 | 2018 | 131 | 0.270 |
Why?
|
| Asia | 4 | 2021 | 618 | 0.270 |
Why?
|
| Postoperative Complications | 12 | 2017 | 15680 | 0.270 |
Why?
|
| Health Promotion | 3 | 2017 | 2208 | 0.270 |
Why?
|
| Research Support as Topic | 2 | 2021 | 699 | 0.270 |
Why?
|
| Postoperative Care | 2 | 2016 | 1478 | 0.260 |
Why?
|
| Pneumonia | 3 | 2018 | 2138 | 0.260 |
Why?
|
| Ivermectin | 2 | 2023 | 47 | 0.260 |
Why?
|
| Fee-for-Service Plans | 8 | 2020 | 705 | 0.260 |
Why?
|
| Insurance, Health | 3 | 2013 | 2500 | 0.260 |
Why?
|
| Outpatients | 10 | 2024 | 1606 | 0.260 |
Why?
|
| Radiation Dosage | 3 | 2018 | 1957 | 0.260 |
Why?
|
| Patient Participation | 4 | 2022 | 1437 | 0.250 |
Why?
|
| Pulmonary Embolism | 6 | 2018 | 2544 | 0.250 |
Why?
|
| Electrocardiography | 8 | 2019 | 6413 | 0.250 |
Why?
|
| Cardiac Resynchronization Therapy Devices | 3 | 2016 | 122 | 0.250 |
Why?
|
| Iron | 2 | 2024 | 1786 | 0.250 |
Why?
|
| Urea | 3 | 2023 | 445 | 0.250 |
Why?
|
| North Carolina | 6 | 2019 | 325 | 0.250 |
Why?
|
| Blood Glucose | 6 | 2024 | 6375 | 0.240 |
Why?
|
| Antidepressive Agents | 3 | 2021 | 2889 | 0.240 |
Why?
|
| Autoimmunity | 1 | 2013 | 1370 | 0.240 |
Why?
|
| Hospice Care | 3 | 2018 | 692 | 0.240 |
Why?
|
| Myocardial Contraction | 2 | 2023 | 1516 | 0.240 |
Why?
|
| Cardiac Surgical Procedures | 4 | 2008 | 3618 | 0.240 |
Why?
|
| Disabled Persons | 1 | 2014 | 1226 | 0.240 |
Why?
|
| Hematinics | 2 | 2019 | 281 | 0.240 |
Why?
|
| Heart Valve Diseases | 3 | 2021 | 1047 | 0.240 |
Why?
|
| Antithrombins | 2 | 2018 | 313 | 0.240 |
Why?
|
| Asia, Southeastern | 3 | 2014 | 113 | 0.240 |
Why?
|
| Liver Diseases | 1 | 2013 | 1301 | 0.240 |
Why?
|
| Pandemics | 11 | 2023 | 8621 | 0.230 |
Why?
|
| Autoantibodies | 1 | 2013 | 2119 | 0.230 |
Why?
|
| Xanthine Oxidase | 2 | 2015 | 69 | 0.230 |
Why?
|
| Linear Models | 9 | 2020 | 5876 | 0.230 |
Why?
|
| Diffusion of Innovation | 3 | 2024 | 730 | 0.230 |
Why?
|
| International Normalized Ratio | 5 | 2023 | 387 | 0.230 |
Why?
|
| Cost-Benefit Analysis | 9 | 2024 | 5507 | 0.230 |
Why?
|
| Drug Therapy, Combination | 11 | 2023 | 6499 | 0.230 |
Why?
|
| Sulfides | 1 | 2024 | 171 | 0.220 |
Why?
|
| Advisory Committees | 3 | 2022 | 789 | 0.220 |
Why?
|
| Europe | 6 | 2020 | 3433 | 0.220 |
Why?
|
| Cardiology Service, Hospital | 2 | 2016 | 242 | 0.220 |
Why?
|
| Peak Expiratory Flow Rate | 2 | 2014 | 144 | 0.220 |
Why?
|
| Hemofiltration | 3 | 2019 | 59 | 0.220 |
Why?
|
| North America | 5 | 2021 | 1282 | 0.220 |
Why?
|
| Vitamin D | 1 | 2017 | 3293 | 0.220 |
Why?
|
| Blood Volume | 3 | 2022 | 550 | 0.220 |
Why?
|
| Cyclopropanes | 1 | 2024 | 431 | 0.210 |
Why?
|
| Acetates | 1 | 2024 | 322 | 0.210 |
Why?
|
| Kidney Function Tests | 5 | 2019 | 680 | 0.210 |
Why?
|
| Liver Function Tests | 2 | 2015 | 524 | 0.210 |
Why?
|
| Research Personnel | 3 | 2022 | 584 | 0.210 |
Why?
|
| Consensus | 7 | 2021 | 3106 | 0.210 |
Why?
|
| Gastrointestinal Hemorrhage | 3 | 2023 | 1130 | 0.210 |
Why?
|
| Antiviral Agents | 1 | 2015 | 3061 | 0.210 |
Why?
|
| Public Health | 4 | 2024 | 2655 | 0.200 |
Why?
|
| Hypolipidemic Agents | 6 | 2014 | 626 | 0.200 |
Why?
|
| Clinical Trials Data Monitoring Committees | 1 | 2022 | 26 | 0.200 |
Why?
|
| Alberta | 3 | 2017 | 66 | 0.200 |
Why?
|
| Acute Kidney Injury | 3 | 2020 | 1935 | 0.200 |
Why?
|
| Androstadienes | 1 | 2023 | 348 | 0.200 |
Why?
|
| Benchmarking | 4 | 2021 | 1043 | 0.190 |
Why?
|
| Growth Differentiation Factor 15 | 2 | 2021 | 192 | 0.190 |
Why?
|
| Drug Monitoring | 3 | 2021 | 966 | 0.190 |
Why?
|
| Splanchnic Circulation | 2 | 2018 | 110 | 0.190 |
Why?
|
| Carbonic Anhydrase Inhibitors | 1 | 2021 | 91 | 0.190 |
Why?
|
| Botulinum Toxins | 1 | 2023 | 188 | 0.190 |
Why?
|
| Hyperuricemia | 2 | 2015 | 224 | 0.190 |
Why?
|
| Ferritins | 3 | 2021 | 598 | 0.190 |
Why?
|
| Plasma Volume | 1 | 2020 | 31 | 0.190 |
Why?
|
| Preoperative Care | 2 | 2014 | 2255 | 0.190 |
Why?
|
| Counseling | 5 | 2017 | 1550 | 0.180 |
Why?
|
| Awards and Prizes | 2 | 2017 | 359 | 0.180 |
Why?
|
| Physicians | 2 | 2011 | 4590 | 0.180 |
Why?
|
| Thoracic Surgery | 1 | 2007 | 722 | 0.180 |
Why?
|
| HIV Long-Term Survivors | 1 | 2021 | 121 | 0.180 |
Why?
|
| Models, Cardiovascular | 2 | 2024 | 974 | 0.180 |
Why?
|
| Mass Screening | 2 | 2014 | 5422 | 0.180 |
Why?
|
| Rest | 2 | 2017 | 915 | 0.180 |
Why?
|
| Enalapril | 2 | 2024 | 313 | 0.180 |
Why?
|
| Jugular Veins | 2 | 2019 | 211 | 0.180 |
Why?
|
| Methylamines | 1 | 2021 | 138 | 0.180 |
Why?
|
| Australia | 3 | 2014 | 1288 | 0.180 |
Why?
|
| Health Status Indicators | 3 | 2018 | 968 | 0.180 |
Why?
|
| Italy | 3 | 2018 | 840 | 0.180 |
Why?
|
| Confidence Intervals | 4 | 2014 | 2932 | 0.180 |
Why?
|
| Patient Compliance | 4 | 2019 | 2689 | 0.180 |
Why?
|
| Potassium | 3 | 2020 | 1318 | 0.180 |
Why?
|
| Dopamine | 4 | 2018 | 1583 | 0.180 |
Why?
|
| Referral and Consultation | 4 | 2016 | 3598 | 0.170 |
Why?
|
| Home Care Services | 3 | 2016 | 653 | 0.170 |
Why?
|
| Sex Characteristics | 6 | 2022 | 2627 | 0.170 |
Why?
|
| Canada | 6 | 2022 | 2128 | 0.170 |
Why?
|
| Intention to Treat Analysis | 5 | 2020 | 422 | 0.170 |
Why?
|
| Hemoglobinometry | 1 | 2019 | 35 | 0.170 |
Why?
|
| Exercise | 6 | 2021 | 5783 | 0.170 |
Why?
|
| Weight Loss | 5 | 2018 | 2683 | 0.170 |
Why?
|
| Coronavirus Infections | 4 | 2020 | 3086 | 0.170 |
Why?
|
| Piperazines | 4 | 2014 | 2520 | 0.170 |
Why?
|
| Internationality | 3 | 2014 | 1005 | 0.170 |
Why?
|
| Renin | 3 | 2021 | 636 | 0.170 |
Why?
|
| Pneumonia, Viral | 4 | 2020 | 3206 | 0.170 |
Why?
|
| Body Mass Index | 8 | 2022 | 12901 | 0.170 |
Why?
|
| Heart Valves | 1 | 2021 | 285 | 0.170 |
Why?
|
| Dyslipidemias | 2 | 2019 | 895 | 0.170 |
Why?
|
| Nitroglycerin | 2 | 2018 | 329 | 0.160 |
Why?
|
| Information Services | 1 | 2020 | 235 | 0.160 |
Why?
|
| Drug Resistance | 2 | 2019 | 1617 | 0.160 |
Why?
|
| Heart Ventricles | 5 | 2019 | 3811 | 0.160 |
Why?
|
| Quinolines | 1 | 2024 | 759 | 0.160 |
Why?
|
| Benzoxazoles | 1 | 2020 | 89 | 0.160 |
Why?
|
| Edema, Cardiac | 1 | 2018 | 19 | 0.160 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 1 | 2020 | 152 | 0.160 |
Why?
|
| Academies and Institutes | 1 | 2021 | 319 | 0.160 |
Why?
|
| Myocardial Reperfusion | 2 | 2012 | 347 | 0.160 |
Why?
|
| Mitral Valve Insufficiency | 2 | 2020 | 1419 | 0.160 |
Why?
|
| Blood Circulation | 2 | 2017 | 249 | 0.160 |
Why?
|
| Ganglia, Sympathetic | 1 | 2018 | 65 | 0.160 |
Why?
|
| Atrial Flutter | 2 | 2018 | 258 | 0.160 |
Why?
|
| Depression | 2 | 2015 | 8033 | 0.160 |
Why?
|
| Hospital Bed Capacity | 3 | 2015 | 210 | 0.160 |
Why?
|
| Device Approval | 1 | 2020 | 165 | 0.160 |
Why?
|
| Myocardium | 5 | 2021 | 4688 | 0.160 |
Why?
|
| Ontario | 2 | 2018 | 405 | 0.160 |
Why?
|
| Morbidity | 4 | 2017 | 1765 | 0.160 |
Why?
|
| Nitrites | 1 | 2018 | 159 | 0.160 |
Why?
|
| Informed Consent | 3 | 2021 | 1007 | 0.150 |
Why?
|
| Thrombectomy | 1 | 2023 | 707 | 0.150 |
Why?
|
| Eligibility Determination | 2 | 2020 | 419 | 0.150 |
Why?
|
| Coronavirus | 1 | 2020 | 149 | 0.150 |
Why?
|
| Premedication | 1 | 2019 | 253 | 0.150 |
Why?
|
| Angiotensins | 3 | 2023 | 143 | 0.150 |
Why?
|
| Early Ambulation | 1 | 2018 | 49 | 0.150 |
Why?
|
| Hemoglobins | 2 | 2021 | 1521 | 0.150 |
Why?
|
| Hematocrit | 1 | 2019 | 630 | 0.150 |
Why?
|
| Myocardial Ischemia | 5 | 2024 | 2161 | 0.150 |
Why?
|
| Sweden | 2 | 2020 | 1381 | 0.150 |
Why?
|
| Fluid Shifts | 1 | 2017 | 20 | 0.150 |
Why?
|
| Hypoalbuminemia | 1 | 2018 | 87 | 0.150 |
Why?
|
| Calcitonin | 1 | 2019 | 330 | 0.150 |
Why?
|
| Galectin 3 | 1 | 2019 | 240 | 0.150 |
Why?
|
| Lower Extremity | 2 | 2017 | 1196 | 0.150 |
Why?
|
| Drug Utilization Review | 2 | 2016 | 251 | 0.150 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 2019 | 179 | 0.150 |
Why?
|
| Gout | 2 | 2023 | 619 | 0.150 |
Why?
|
| Cluster Analysis | 4 | 2020 | 2698 | 0.150 |
Why?
|
| Hypertension | 6 | 2024 | 8595 | 0.150 |
Why?
|
| Hypertension, Pulmonary | 3 | 2017 | 1570 | 0.150 |
Why?
|
| Coronary Disease | 4 | 2015 | 5993 | 0.140 |
Why?
|
| Journal Impact Factor | 1 | 2019 | 156 | 0.140 |
Why?
|
| Interleukin-6 | 3 | 2023 | 3207 | 0.140 |
Why?
|
| Aortic Diseases | 1 | 2023 | 736 | 0.140 |
Why?
|
| Receptors, Mineralocorticoid | 1 | 2018 | 164 | 0.140 |
Why?
|
| After-Hours Care | 1 | 2018 | 101 | 0.140 |
Why?
|
| Case-Control Studies | 11 | 2020 | 22041 | 0.140 |
Why?
|
| Antihypertensive Agents | 2 | 2012 | 2063 | 0.140 |
Why?
|
| Deglutition Disorders | 2 | 2013 | 627 | 0.140 |
Why?
|
| Sex Distribution | 6 | 2019 | 2295 | 0.140 |
Why?
|
| Mississippi | 4 | 2017 | 93 | 0.140 |
Why?
|
| Diabetic Foot | 1 | 2021 | 381 | 0.140 |
Why?
|
| Models, Statistical | 5 | 2017 | 5073 | 0.140 |
Why?
|
| Dilatation, Pathologic | 1 | 2018 | 527 | 0.140 |
Why?
|
| Primary Graft Dysfunction | 1 | 2017 | 111 | 0.140 |
Why?
|
| Prediabetic State | 1 | 2022 | 550 | 0.140 |
Why?
|
| Kidney Failure, Chronic | 3 | 2019 | 2469 | 0.140 |
Why?
|
| Policy Making | 3 | 2020 | 539 | 0.140 |
Why?
|
| Reimbursement, Incentive | 3 | 2012 | 543 | 0.140 |
Why?
|
| Allopurinol | 2 | 2015 | 200 | 0.140 |
Why?
|
| Interdisciplinary Communication | 2 | 2020 | 934 | 0.140 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 2 | 2023 | 379 | 0.130 |
Why?
|
| Patients | 2 | 2024 | 906 | 0.130 |
Why?
|
| Prevalence | 15 | 2024 | 15687 | 0.130 |
Why?
|
| Policy | 1 | 2020 | 511 | 0.130 |
Why?
|
| Donor Selection | 1 | 2018 | 228 | 0.130 |
Why?
|
| Unnecessary Procedures | 1 | 2019 | 413 | 0.130 |
Why?
|
| Ethics, Medical | 1 | 2021 | 787 | 0.130 |
Why?
|
| Risk Adjustment | 2 | 2010 | 601 | 0.130 |
Why?
|
| Endovascular Procedures | 2 | 2023 | 2135 | 0.130 |
Why?
|
| Recurrence | 7 | 2020 | 8487 | 0.130 |
Why?
|
| Longitudinal Studies | 6 | 2024 | 14482 | 0.130 |
Why?
|
| Critical Care | 4 | 2017 | 2699 | 0.130 |
Why?
|
| Ambulances | 1 | 2016 | 92 | 0.130 |
Why?
|
| Tissue and Organ Procurement | 3 | 2018 | 944 | 0.130 |
Why?
|
| Patient Care Management | 1 | 2019 | 303 | 0.130 |
Why?
|
| Continuity of Patient Care | 2 | 2013 | 1067 | 0.130 |
Why?
|
| Muscular Diseases | 1 | 2019 | 551 | 0.120 |
Why?
|
| Needs Assessment | 3 | 2018 | 1137 | 0.120 |
Why?
|
| Naphthyridines | 1 | 2016 | 141 | 0.120 |
Why?
|
| Dietary Supplements | 2 | 2019 | 3389 | 0.120 |
Why?
|
| Lipoprotein(a) | 1 | 2020 | 499 | 0.120 |
Why?
|
| Anti-Infective Agents | 1 | 2022 | 982 | 0.120 |
Why?
|
| Guanylate Cyclase | 2 | 2020 | 205 | 0.120 |
Why?
|
| Monitoring, Physiologic | 2 | 2019 | 1784 | 0.120 |
Why?
|
| Geographic Information Systems | 1 | 2017 | 280 | 0.120 |
Why?
|
| Episode of Care | 2 | 2013 | 127 | 0.120 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2019 | 346 | 0.120 |
Why?
|
| Vulnerable Populations | 1 | 2020 | 696 | 0.120 |
Why?
|
| Bicarbonates | 1 | 2016 | 304 | 0.120 |
Why?
|
| Video Games | 1 | 2017 | 190 | 0.120 |
Why?
|
| Wind | 1 | 2014 | 41 | 0.120 |
Why?
|
| Placebo Effect | 1 | 2018 | 511 | 0.120 |
Why?
|
| Intensive Care Units | 3 | 2020 | 3737 | 0.120 |
Why?
|
| Natriuretic Peptides | 2 | 2012 | 156 | 0.120 |
Why?
|
| Ancillary Services, Hospital | 1 | 2014 | 23 | 0.120 |
Why?
|
| Neoplasms | 2 | 2024 | 22066 | 0.120 |
Why?
|
| Fatigue | 2 | 2019 | 1544 | 0.120 |
Why?
|
| Combined Modality Therapy | 4 | 2016 | 8551 | 0.120 |
Why?
|
| Cholesterol, LDL | 3 | 2014 | 2422 | 0.120 |
Why?
|
| Vaccines | 1 | 2023 | 833 | 0.120 |
Why?
|
| Heart Atria | 2 | 2019 | 1344 | 0.120 |
Why?
|
| Lipoproteins, HDL | 1 | 2019 | 667 | 0.120 |
Why?
|
| Recombinant Proteins | 5 | 2017 | 6543 | 0.120 |
Why?
|
| HIV | 2 | 2019 | 1579 | 0.120 |
Why?
|
| Endothelin-1 | 1 | 2015 | 302 | 0.120 |
Why?
|
| Patient Dropouts | 1 | 2016 | 412 | 0.120 |
Why?
|
| Hydroxychloroquine | 3 | 2023 | 428 | 0.110 |
Why?
|
| Hospitals, University | 1 | 2015 | 568 | 0.110 |
Why?
|
| Critical Illness | 3 | 2022 | 2709 | 0.110 |
Why?
|
| France | 1 | 2015 | 511 | 0.110 |
Why?
|
| Least-Squares Analysis | 3 | 2020 | 369 | 0.110 |
Why?
|
| Subarachnoid Hemorrhage | 2 | 2013 | 1032 | 0.110 |
Why?
|
| Humidity | 1 | 2014 | 205 | 0.110 |
Why?
|
| Long-Term Care | 1 | 2018 | 628 | 0.110 |
Why?
|
| Fluvoxamine | 2 | 2023 | 78 | 0.110 |
Why?
|
| Specialization | 1 | 2018 | 779 | 0.110 |
Why?
|
| Life Expectancy | 1 | 2020 | 1249 | 0.110 |
Why?
|
| China | 2 | 2018 | 2340 | 0.110 |
Why?
|
| Drug Approval | 1 | 2020 | 816 | 0.110 |
Why?
|
| Insurance, Health, Reimbursement | 2 | 2019 | 385 | 0.110 |
Why?
|
| Amyloidosis | 1 | 2020 | 818 | 0.110 |
Why?
|
| Calcium Channel Blockers | 2 | 2013 | 694 | 0.110 |
Why?
|
| Disclosure | 1 | 2018 | 738 | 0.110 |
Why?
|
| Glucose Metabolism Disorders | 1 | 2013 | 52 | 0.110 |
Why?
|
| gamma-Glutamyltransferase | 1 | 2013 | 144 | 0.110 |
Why?
|
| Cyclohexanes | 1 | 2013 | 152 | 0.100 |
Why?
|
| Drug Substitution | 1 | 2015 | 296 | 0.100 |
Why?
|
| Emergency Treatment | 1 | 2016 | 498 | 0.100 |
Why?
|
| Microspheres | 1 | 2015 | 785 | 0.100 |
Why?
|
| Mitochondrial Diseases | 1 | 2016 | 340 | 0.100 |
Why?
|
| Waiting Lists | 4 | 2016 | 754 | 0.100 |
Why?
|
| Hemoglobinuria, Paroxysmal | 1 | 2013 | 95 | 0.100 |
Why?
|
| Hypoglycemia | 1 | 2019 | 888 | 0.100 |
Why?
|
| Diagnosis-Related Groups | 2 | 2011 | 450 | 0.100 |
Why?
|
| Program Evaluation | 5 | 2014 | 2494 | 0.100 |
Why?
|
| Clinical Audit | 1 | 2012 | 30 | 0.100 |
Why?
|
| Conflict of Interest | 1 | 2017 | 549 | 0.100 |
Why?
|
| Receptors, Virus | 1 | 2015 | 639 | 0.100 |
Why?
|
| Lipids | 2 | 2023 | 3336 | 0.100 |
Why?
|
| Urination | 1 | 2013 | 202 | 0.100 |
Why?
|
| Smoking Cessation | 6 | 2016 | 2064 | 0.100 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2021 | 1300 | 0.100 |
Why?
|
| American Hospital Association | 1 | 2011 | 27 | 0.100 |
Why?
|
| Anticholesteremic Agents | 1 | 2019 | 988 | 0.100 |
Why?
|
| Ticlopidine | 2 | 2023 | 895 | 0.100 |
Why?
|
| Medical Records Systems, Computerized | 2 | 2015 | 1191 | 0.100 |
Why?
|
| Medicare Part A | 1 | 2011 | 40 | 0.100 |
Why?
|
| Thoracic Surgical Procedures | 2 | 2006 | 347 | 0.100 |
Why?
|
| Smoking | 4 | 2024 | 9070 | 0.100 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2022 | 1455 | 0.100 |
Why?
|
| Phenylalanine | 1 | 2013 | 365 | 0.090 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 3 | 2018 | 418 | 0.090 |
Why?
|
| Hong Kong | 1 | 2011 | 161 | 0.090 |
Why?
|
| South America | 1 | 2011 | 181 | 0.090 |
Why?
|
| Mitral Valve | 2 | 2017 | 1486 | 0.090 |
Why?
|
| Vascular Resistance | 1 | 2014 | 932 | 0.090 |
Why?
|
| Hemolysis | 1 | 2013 | 423 | 0.090 |
Why?
|
| Angioedema | 1 | 2012 | 192 | 0.090 |
Why?
|
| Interferon-alpha | 1 | 2015 | 919 | 0.090 |
Why?
|
| Sodium | 3 | 2022 | 1601 | 0.090 |
Why?
|
| Tissue Donors | 2 | 2018 | 2314 | 0.090 |
Why?
|
| Sodium-Glucose Transporter 2 | 2 | 2022 | 98 | 0.090 |
Why?
|
| C-Reactive Protein | 3 | 2023 | 3822 | 0.090 |
Why?
|
| Publishing | 1 | 2018 | 837 | 0.090 |
Why?
|
| Bacteria | 1 | 2021 | 2196 | 0.090 |
Why?
|
| Albumins | 1 | 2013 | 577 | 0.090 |
Why?
|
| Health Personnel | 5 | 2023 | 3310 | 0.090 |
Why?
|
| Insurance Coverage | 2 | 2013 | 1939 | 0.090 |
Why?
|
| Algorithms | 3 | 2022 | 13967 | 0.090 |
Why?
|
| Echocardiography | 5 | 2020 | 4980 | 0.090 |
Why?
|
| Residence Characteristics | 3 | 2016 | 2058 | 0.090 |
Why?
|
| Taiwan | 1 | 2011 | 503 | 0.090 |
Why?
|
| Vancomycin | 1 | 2013 | 503 | 0.090 |
Why?
|
| Purines | 4 | 2014 | 601 | 0.090 |
Why?
|
| Certification | 1 | 2013 | 423 | 0.090 |
Why?
|
| Regression Analysis | 3 | 2015 | 6361 | 0.090 |
Why?
|
| Blood Urea Nitrogen | 3 | 2014 | 187 | 0.090 |
Why?
|
| Pneumonia, Bacterial | 1 | 2013 | 319 | 0.090 |
Why?
|
| Medical Records | 1 | 2015 | 1407 | 0.090 |
Why?
|
| Protein Precursors | 3 | 2020 | 1135 | 0.090 |
Why?
|
| Income | 1 | 2018 | 1876 | 0.080 |
Why?
|
| Dystonia | 1 | 2013 | 364 | 0.080 |
Why?
|
| Metabolic Diseases | 1 | 2016 | 685 | 0.080 |
Why?
|
| Weight Gain | 2 | 2017 | 2347 | 0.080 |
Why?
|
| Aortic Valve Stenosis | 2 | 2012 | 2064 | 0.080 |
Why?
|
| Patient Care Planning | 1 | 2015 | 909 | 0.080 |
Why?
|
| Polysaccharides | 1 | 2016 | 1016 | 0.080 |
Why?
|
| Medically Uninsured | 2 | 2013 | 843 | 0.080 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2014 | 853 | 0.080 |
Why?
|
| Time and Motion Studies | 1 | 2009 | 143 | 0.080 |
Why?
|
| Hospital Administration | 2 | 2010 | 354 | 0.080 |
Why?
|
| Coronary Artery Bypass, Off-Pump | 1 | 2009 | 65 | 0.080 |
Why?
|
| Receptors, Angiotensin | 2 | 2021 | 141 | 0.080 |
Why?
|
| Muscle, Smooth | 1 | 2013 | 924 | 0.080 |
Why?
|
| Respiratory Tract Infections | 1 | 2017 | 1001 | 0.080 |
Why?
|
| HIV Infections | 3 | 2021 | 17159 | 0.080 |
Why?
|
| Bacteremia | 2 | 2013 | 979 | 0.080 |
Why?
|
| Reproducibility of Results | 5 | 2020 | 20048 | 0.080 |
Why?
|
| Dementia | 1 | 2023 | 2638 | 0.080 |
Why?
|
| Anemia | 1 | 2018 | 1511 | 0.080 |
Why?
|
| Observer Variation | 1 | 2014 | 2596 | 0.080 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2018 | 1200 | 0.080 |
Why?
|
| Hospital Charges | 1 | 2010 | 359 | 0.080 |
Why?
|
| Administration, Inhalation | 2 | 2023 | 1156 | 0.080 |
Why?
|
| Anti-Retroviral Agents | 1 | 2018 | 1780 | 0.080 |
Why?
|
| Obesity | 3 | 2022 | 12915 | 0.080 |
Why?
|
| Hospitals, Rural | 1 | 2009 | 175 | 0.080 |
Why?
|
| Young Adult | 12 | 2024 | 58673 | 0.070 |
Why?
|
| Temperature | 1 | 2014 | 2221 | 0.070 |
Why?
|
| Occupational Exposure | 1 | 2018 | 1809 | 0.070 |
Why?
|
| Syncope | 2 | 2021 | 428 | 0.070 |
Why?
|
| Health Services Accessibility | 4 | 2013 | 5396 | 0.070 |
Why?
|
| Coronary Stenosis | 1 | 2014 | 820 | 0.070 |
Why?
|
| Pyridones | 3 | 2018 | 788 | 0.070 |
Why?
|
| Prescriptions | 1 | 2010 | 388 | 0.070 |
Why?
|
| Cross-Sectional Studies | 8 | 2022 | 25928 | 0.070 |
Why?
|
| Heart Arrest, Induced | 1 | 2009 | 357 | 0.070 |
Why?
|
| Medical Record Linkage | 1 | 2009 | 289 | 0.070 |
Why?
|
| Hospitals, Urban | 1 | 2009 | 499 | 0.070 |
Why?
|
| Blood Coagulation | 1 | 2013 | 1156 | 0.070 |
Why?
|
| International Cooperation | 1 | 2014 | 1436 | 0.070 |
Why?
|
| Arrhythmogenic Right Ventricular Dysplasia | 1 | 2009 | 162 | 0.070 |
Why?
|
| Motor Activity | 1 | 2017 | 2687 | 0.070 |
Why?
|
| Polypharmacy | 2 | 2023 | 307 | 0.070 |
Why?
|
| Transferrin | 2 | 2019 | 284 | 0.070 |
Why?
|
| Prilocaine | 1 | 2006 | 21 | 0.070 |
Why?
|
| Ischemia | 1 | 2015 | 1893 | 0.070 |
Why?
|
| Skilled Nursing Facilities | 1 | 2011 | 398 | 0.070 |
Why?
|
| Clinical Protocols | 3 | 2019 | 1439 | 0.070 |
Why?
|
| Fibrosis | 3 | 2021 | 2042 | 0.070 |
Why?
|
| Poverty | 1 | 2018 | 2695 | 0.070 |
Why?
|
| Receptors, Cell Surface | 1 | 2015 | 2825 | 0.070 |
Why?
|
| Databases as Topic | 1 | 2008 | 474 | 0.070 |
Why?
|
| Prosthesis Design | 3 | 2021 | 2127 | 0.070 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 2 | 2018 | 323 | 0.070 |
Why?
|
| Exercise Therapy | 1 | 2013 | 920 | 0.070 |
Why?
|
| Heart | 2 | 2017 | 4392 | 0.070 |
Why?
|
| Sulfonamides | 1 | 2015 | 1973 | 0.060 |
Why?
|
| Thyroid Neoplasms | 1 | 2019 | 2332 | 0.060 |
Why?
|
| Women's Health | 1 | 2015 | 2057 | 0.060 |
Why?
|
| Coronary Angiography | 2 | 2014 | 4560 | 0.060 |
Why?
|
| Systole | 3 | 2017 | 947 | 0.060 |
Why?
|
| Caregivers | 1 | 2017 | 2222 | 0.060 |
Why?
|
| Program Development | 1 | 2011 | 1297 | 0.060 |
Why?
|
| Life Style | 1 | 2017 | 3888 | 0.060 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2009 | 859 | 0.060 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2013 | 1004 | 0.060 |
Why?
|
| Obesity, Morbid | 1 | 2016 | 1287 | 0.060 |
Why?
|
| Statistics, Nonparametric | 3 | 2016 | 2852 | 0.060 |
Why?
|
| Decision Making | 2 | 2017 | 3924 | 0.060 |
Why?
|
| Diastole | 2 | 2020 | 788 | 0.060 |
Why?
|
| Software | 1 | 2019 | 4420 | 0.060 |
Why?
|
| Clinical Competence | 2 | 2012 | 4786 | 0.060 |
Why?
|
| Procollagen | 2 | 2017 | 188 | 0.060 |
Why?
|
| Membrane Glycoproteins | 1 | 2015 | 3731 | 0.060 |
Why?
|
| Graft Rejection | 2 | 2016 | 4423 | 0.060 |
Why?
|
| Oxygen | 1 | 2016 | 4189 | 0.060 |
Why?
|
| Sodium-Glucose Transport Proteins | 1 | 2024 | 13 | 0.060 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2008 | 498 | 0.060 |
Why?
|
| Respiratory Sounds | 2 | 2019 | 697 | 0.060 |
Why?
|
| Posture | 2 | 2019 | 954 | 0.060 |
Why?
|
| Opioid-Related Disorders | 1 | 2019 | 2135 | 0.060 |
Why?
|
| Staphylococcal Infections | 1 | 2013 | 1405 | 0.060 |
Why?
|
| Heparin | 1 | 2011 | 1655 | 0.060 |
Why?
|
| Remission Induction | 2 | 2023 | 2394 | 0.060 |
Why?
|
| Leukotriene Antagonists | 1 | 2024 | 124 | 0.060 |
Why?
|
| Vascular Surgical Procedures | 2 | 2021 | 1469 | 0.060 |
Why?
|
| Prosthesis Implantation | 1 | 2008 | 593 | 0.060 |
Why?
|
| Inflammation | 3 | 2023 | 10757 | 0.060 |
Why?
|
| Urine | 2 | 2017 | 363 | 0.060 |
Why?
|
| Kansas | 1 | 2023 | 39 | 0.060 |
Why?
|
| Homeostasis | 1 | 2014 | 3305 | 0.060 |
Why?
|
| Cross Infection | 1 | 2013 | 1434 | 0.060 |
Why?
|
| Health Expenditures | 2 | 2018 | 2359 | 0.050 |
Why?
|
| Treatment Failure | 2 | 2020 | 2646 | 0.050 |
Why?
|
| Hypovolemia | 1 | 2023 | 48 | 0.050 |
Why?
|
| Asymptomatic Diseases | 2 | 2018 | 582 | 0.050 |
Why?
|
| Lidocaine | 1 | 2006 | 538 | 0.050 |
Why?
|
| Albuminuria | 2 | 2020 | 659 | 0.050 |
Why?
|
| Pyrazoles | 3 | 2018 | 1992 | 0.050 |
Why?
|
| Uric Acid | 2 | 2023 | 807 | 0.050 |
Why?
|
| Data Interpretation, Statistical | 3 | 2019 | 2696 | 0.050 |
Why?
|
| Patient Satisfaction | 1 | 2015 | 3451 | 0.050 |
Why?
|
| Ultrasonography | 4 | 2017 | 5960 | 0.050 |
Why?
|
| Arrhythmias, Cardiac | 3 | 2019 | 2255 | 0.050 |
Why?
|
| Laparotomy | 1 | 2004 | 468 | 0.050 |
Why?
|
| Growth Differentiation Factors | 1 | 2023 | 99 | 0.050 |
Why?
|
| Directive Counseling | 2 | 2014 | 170 | 0.050 |
Why?
|
| Troponin T | 2 | 2023 | 774 | 0.050 |
Why?
|
| Cross-Over Studies | 2 | 2018 | 2061 | 0.050 |
Why?
|
| Physician's Role | 1 | 2008 | 920 | 0.050 |
Why?
|
| Oxidative Stress | 4 | 2015 | 3107 | 0.050 |
Why?
|
| Colchicine | 1 | 2023 | 261 | 0.050 |
Why?
|
| Social Class | 2 | 2022 | 2005 | 0.050 |
Why?
|
| Hypercholesterolemia | 1 | 2008 | 1155 | 0.050 |
Why?
|
| Education, Professional | 1 | 2021 | 51 | 0.050 |
Why?
|
| Adolescent | 10 | 2023 | 87747 | 0.050 |
Why?
|
| Academic Medical Centers | 3 | 2020 | 2753 | 0.050 |
Why?
|
| Phenylephrine | 1 | 2022 | 293 | 0.050 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2022 | 273 | 0.050 |
Why?
|
| Gangrene | 1 | 2021 | 91 | 0.050 |
Why?
|
| Maryland | 1 | 2021 | 275 | 0.050 |
Why?
|
| Glucose | 2 | 2022 | 4361 | 0.040 |
Why?
|
| Atrial Natriuretic Factor | 2 | 2013 | 350 | 0.040 |
Why?
|
| Efficiency, Organizational | 2 | 2019 | 697 | 0.040 |
Why?
|
| Drug Repositioning | 1 | 2022 | 231 | 0.040 |
Why?
|
| Vaccines, Inactivated | 1 | 2021 | 180 | 0.040 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2020 | 71 | 0.040 |
Why?
|
| New York | 1 | 2022 | 874 | 0.040 |
Why?
|
| Tachycardia, Ventricular | 1 | 2009 | 1302 | 0.040 |
Why?
|
| Cooperative Behavior | 2 | 2020 | 1500 | 0.040 |
Why?
|
| Sarcoidosis | 1 | 2005 | 520 | 0.040 |
Why?
|
| Insulin | 1 | 2014 | 6592 | 0.040 |
Why?
|
| Venous Pressure | 1 | 2019 | 57 | 0.040 |
Why?
|
| Internet | 3 | 2023 | 3074 | 0.040 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2023 | 568 | 0.040 |
Why?
|
| Anesthetics, Local | 1 | 2006 | 1001 | 0.040 |
Why?
|
| Thrombosis | 1 | 2013 | 3052 | 0.040 |
Why?
|
| Insurance, Pharmaceutical Services | 2 | 2013 | 345 | 0.040 |
Why?
|
| Echocardiography, Doppler | 2 | 2014 | 900 | 0.040 |
Why?
|
| Immunophenotyping | 1 | 2024 | 1870 | 0.040 |
Why?
|
| Colorectal Neoplasms | 1 | 2019 | 6855 | 0.040 |
Why?
|
| Norepinephrine | 1 | 2022 | 900 | 0.040 |
Why?
|
| Cholesterol | 1 | 2008 | 2925 | 0.040 |
Why?
|
| Inorganic Chemicals | 1 | 2018 | 10 | 0.040 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2013 | 3159 | 0.040 |
Why?
|
| Drug Dosage Calculations | 1 | 2019 | 118 | 0.040 |
Why?
|
| Azithromycin | 1 | 2020 | 201 | 0.040 |
Why?
|
| Cyclosporine | 1 | 2022 | 778 | 0.040 |
Why?
|
| Vascular Capacitance | 1 | 2018 | 4 | 0.040 |
Why?
|
| Blood Component Removal | 1 | 2020 | 132 | 0.040 |
Why?
|
| Catheter Ablation | 1 | 2012 | 2755 | 0.040 |
Why?
|
| Heart Defects, Congenital | 1 | 2016 | 4668 | 0.040 |
Why?
|
| Heart Valve Prosthesis | 2 | 2021 | 1494 | 0.040 |
Why?
|
| Atrial Function, Left | 1 | 2019 | 186 | 0.040 |
Why?
|
| Health Policy | 1 | 2011 | 2678 | 0.040 |
Why?
|
| Age Distribution | 2 | 2018 | 2893 | 0.040 |
Why?
|
| Syndrome | 3 | 2010 | 3278 | 0.040 |
Why?
|
| Acetylglucosaminidase | 1 | 2018 | 67 | 0.040 |
Why?
|
| Attitude of Health Personnel | 1 | 2012 | 3870 | 0.040 |
Why?
|
| Communication | 1 | 2012 | 3846 | 0.040 |
Why?
|
| Renal Dialysis | 2 | 2018 | 1802 | 0.040 |
Why?
|
| Hospitals, Community | 1 | 2020 | 367 | 0.040 |
Why?
|
| Antidotes | 1 | 2018 | 138 | 0.040 |
Why?
|
| Public Opinion | 1 | 2021 | 481 | 0.040 |
Why?
|
| Immobilization | 1 | 2018 | 230 | 0.040 |
Why?
|
| Reference Standards | 1 | 2021 | 1004 | 0.040 |
Why?
|
| Postoperative Period | 2 | 2017 | 1821 | 0.040 |
Why?
|
| Prescription Drugs | 2 | 2015 | 630 | 0.040 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2020 | 459 | 0.040 |
Why?
|
| Liver | 1 | 2013 | 7512 | 0.040 |
Why?
|
| United States Food and Drug Administration | 2 | 2020 | 1675 | 0.040 |
Why?
|
| Drug Industry | 1 | 2024 | 789 | 0.040 |
Why?
|
| Sample Size | 1 | 2020 | 840 | 0.040 |
Why?
|
| Cardiac Output, Low | 1 | 2018 | 192 | 0.040 |
Why?
|
| Pain Measurement | 3 | 2015 | 3514 | 0.040 |
Why?
|
| Galectins | 1 | 2019 | 282 | 0.030 |
Why?
|
| Renal Circulation | 1 | 2017 | 292 | 0.030 |
Why?
|
| Health Care Surveys | 2 | 2017 | 2434 | 0.030 |
Why?
|
| Phenotype | 1 | 2014 | 16543 | 0.030 |
Why?
|
| Precipitating Factors | 1 | 2016 | 51 | 0.030 |
Why?
|
| Financing, Government | 1 | 2020 | 472 | 0.030 |
Why?
|
| Thyroid Hormones | 1 | 2019 | 403 | 0.030 |
Why?
|
| Animals | 6 | 2017 | 167940 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2011 | 14656 | 0.030 |
Why?
|
| Azotemia | 1 | 2015 | 8 | 0.030 |
Why?
|
| Aorta | 1 | 2023 | 2042 | 0.030 |
Why?
|
| Medication Therapy Management | 1 | 2016 | 132 | 0.030 |
Why?
|
| Serum Albumin | 1 | 2018 | 674 | 0.030 |
Why?
|
| Microvessels | 1 | 2019 | 572 | 0.030 |
Why?
|
| World Health Organization | 1 | 2021 | 1319 | 0.030 |
Why?
|
| Meteorological Concepts | 1 | 2014 | 31 | 0.030 |
Why?
|
| Mitochondria, Heart | 1 | 2016 | 229 | 0.030 |
Why?
|
| Ventricular Remodeling | 1 | 2022 | 1259 | 0.030 |
Why?
|
| Diagnosis, Differential | 3 | 2019 | 12968 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2021 | 1724 | 0.030 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 3 | 2016 | 3223 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2017 | 555 | 0.030 |
Why?
|
| Immunoassay | 1 | 2018 | 748 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2013 | 7400 | 0.030 |
Why?
|
| Orthopedic Procedures | 1 | 2004 | 1262 | 0.030 |
Why?
|
| Biopsy | 1 | 2006 | 6775 | 0.030 |
Why?
|
| Statistics as Topic | 2 | 2012 | 2363 | 0.030 |
Why?
|
| Blood Proteins | 1 | 2019 | 1172 | 0.030 |
Why?
|
| Education | 1 | 2017 | 535 | 0.030 |
Why?
|
| Placebos | 1 | 2018 | 1672 | 0.030 |
Why?
|
| Glucocorticoids | 1 | 2023 | 2143 | 0.030 |
Why?
|
| Poisson Distribution | 1 | 2015 | 507 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2024 | 5873 | 0.030 |
Why?
|
| Delayed-Action Preparations | 1 | 2017 | 961 | 0.030 |
Why?
|
| Coagulase | 1 | 2013 | 54 | 0.030 |
Why?
|
| Sotalol | 1 | 2013 | 47 | 0.030 |
Why?
|
| Weather | 1 | 2014 | 227 | 0.030 |
Why?
|
| Veins | 1 | 2017 | 765 | 0.030 |
Why?
|
| Minority Groups | 2 | 2013 | 1199 | 0.030 |
Why?
|
| Gout Suppressants | 1 | 2015 | 178 | 0.030 |
Why?
|
| Echocardiography, Stress | 1 | 2014 | 134 | 0.030 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2019 | 785 | 0.030 |
Why?
|
| Adrenomedullin | 1 | 2013 | 85 | 0.030 |
Why?
|
| Actigraphy | 1 | 2017 | 518 | 0.030 |
Why?
|
| Xanthines | 1 | 2013 | 122 | 0.030 |
Why?
|
| Confidentiality | 1 | 2017 | 610 | 0.030 |
Why?
|
| Ultrasonography, Doppler, Duplex | 1 | 2014 | 200 | 0.030 |
Why?
|
| Staphylococcus | 1 | 2013 | 156 | 0.030 |
Why?
|
| Netherlands | 1 | 2017 | 2213 | 0.030 |
Why?
|
| Saline Solution, Hypertonic | 1 | 2013 | 114 | 0.030 |
Why?
|
| Medical Staff Privileges | 1 | 2012 | 15 | 0.030 |
Why?
|
| Telephone | 1 | 2016 | 623 | 0.030 |
Why?
|
| Withholding Treatment | 1 | 2017 | 613 | 0.030 |
Why?
|
| Free Radical Scavengers | 1 | 2013 | 211 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2023 | 3483 | 0.030 |
Why?
|
| Diabetic Neuropathies | 1 | 2016 | 406 | 0.030 |
Why?
|
| Physical Examination | 1 | 2018 | 1244 | 0.030 |
Why?
|
| Markov Chains | 1 | 2016 | 971 | 0.030 |
Why?
|
| Kenya | 1 | 2015 | 749 | 0.030 |
Why?
|
| Achievement | 1 | 2013 | 289 | 0.020 |
Why?
|
| California | 1 | 2016 | 1416 | 0.020 |
Why?
|
| Cellulitis | 1 | 2013 | 208 | 0.020 |
Why?
|
| Glycopeptides | 1 | 2013 | 220 | 0.020 |
Why?
|
| Demography | 1 | 2016 | 1650 | 0.020 |
Why?
|
| Knowledge Bases | 1 | 2012 | 98 | 0.020 |
Why?
|
| Office Visits | 1 | 2016 | 597 | 0.020 |
Why?
|
| Thyroid Function Tests | 1 | 2012 | 290 | 0.020 |
Why?
|
| Vascular Patency | 1 | 2014 | 901 | 0.020 |
Why?
|
| Organ Size | 1 | 2016 | 2249 | 0.020 |
Why?
|
| Bundle-Branch Block | 1 | 2013 | 281 | 0.020 |
Why?
|
| Respiratory Rate | 1 | 2012 | 175 | 0.020 |
Why?
|
| Saphenous Vein | 1 | 2014 | 538 | 0.020 |
Why?
|
| Diet, Sodium-Restricted | 1 | 2013 | 291 | 0.020 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2013 | 253 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 2017 | 1679 | 0.020 |
Why?
|
| Coronary Circulation | 1 | 2017 | 1578 | 0.020 |
Why?
|
| Pain | 1 | 2006 | 5066 | 0.020 |
Why?
|
| Anxiety Disorders | 1 | 2022 | 2711 | 0.020 |
Why?
|
| Remission, Spontaneous | 1 | 2011 | 383 | 0.020 |
Why?
|
| Tricuspid Valve | 1 | 2014 | 409 | 0.020 |
Why?
|
| Infant, Very Low Birth Weight | 1 | 2013 | 406 | 0.020 |
Why?
|
| Pericardial Effusion | 1 | 2012 | 247 | 0.020 |
Why?
|
| Monte Carlo Method | 1 | 2016 | 1256 | 0.020 |
Why?
|
| Nonlinear Dynamics | 1 | 2013 | 493 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2016 | 2222 | 0.020 |
Why?
|
| Mitochondria | 1 | 2023 | 3598 | 0.020 |
Why?
|
| Survivors | 1 | 2021 | 2367 | 0.020 |
Why?
|
| von Willebrand Diseases | 1 | 2011 | 132 | 0.020 |
Why?
|
| Health Priorities | 1 | 2013 | 376 | 0.020 |
Why?
|
| Private Sector | 1 | 2013 | 398 | 0.020 |
Why?
|
| Comoros | 1 | 2009 | 12 | 0.020 |
Why?
|
| Obesity, Abdominal | 1 | 2013 | 375 | 0.020 |
Why?
|
| Bisoprolol | 1 | 2009 | 9 | 0.020 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2011 | 346 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2018 | 4127 | 0.020 |
Why?
|
| Health Care Rationing | 1 | 2013 | 435 | 0.020 |
Why?
|
| Massachusetts | 1 | 2022 | 8805 | 0.020 |
Why?
|
| Joint Commission on Accreditation of Healthcare Organizations | 1 | 2009 | 92 | 0.020 |
Why?
|
| Waist Circumference | 1 | 2013 | 922 | 0.020 |
Why?
|
| Utilization Review | 1 | 2010 | 383 | 0.020 |
Why?
|
| Thiazoles | 1 | 2016 | 1509 | 0.020 |
Why?
|
| Epidemiologic Methods | 1 | 2014 | 1344 | 0.020 |
Why?
|
| Diabetic Nephropathies | 1 | 2016 | 988 | 0.020 |
Why?
|
| Metoprolol | 1 | 2009 | 92 | 0.020 |
Why?
|
| Propanolamines | 1 | 2009 | 162 | 0.020 |
Why?
|
| Quality Control | 1 | 2011 | 827 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2019 | 6830 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2019 | 3764 | 0.020 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2014 | 572 | 0.020 |
Why?
|
| Age of Onset | 1 | 2015 | 3302 | 0.020 |
Why?
|
| Fatty Acids | 1 | 2016 | 1805 | 0.020 |
Why?
|
| Angiography | 1 | 2014 | 1605 | 0.020 |
Why?
|
| Benzoates | 1 | 2009 | 212 | 0.020 |
Why?
|
| Platelet Aggregation | 1 | 2011 | 805 | 0.020 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2016 | 936 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2016 | 6242 | 0.020 |
Why?
|
| Body Weight | 1 | 2018 | 4613 | 0.020 |
Why?
|
| Carbazoles | 1 | 2009 | 221 | 0.020 |
Why?
|
| Electronic Mail | 1 | 2009 | 207 | 0.020 |
Why?
|
| Anxiety | 1 | 2022 | 4532 | 0.020 |
Why?
|
| Health Maintenance Organizations | 1 | 2010 | 660 | 0.020 |
Why?
|
| Causality | 1 | 2013 | 1241 | 0.020 |
Why?
|
| Hospices | 1 | 2010 | 256 | 0.020 |
Why?
|
| Drug Costs | 1 | 2015 | 1184 | 0.020 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2014 | 1038 | 0.020 |
Why?
|
| Metabolomics | 1 | 2016 | 1626 | 0.020 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2014 | 1430 | 0.020 |
Why?
|
| Geriatric Assessment | 1 | 2014 | 1405 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2011 | 1635 | 0.020 |
Why?
|
| Creatine Kinase, MB Form | 1 | 2007 | 211 | 0.020 |
Why?
|
| Drug Hypersensitivity | 1 | 2015 | 912 | 0.020 |
Why?
|
| Drug Delivery Systems | 1 | 2018 | 2218 | 0.020 |
Why?
|
| Economics, Hospital | 1 | 2008 | 212 | 0.020 |
Why?
|
| Cerebrovascular Disorders | 1 | 2013 | 1500 | 0.020 |
Why?
|
| Walking | 1 | 2013 | 1190 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2019 | 6210 | 0.020 |
Why?
|
| Urban Population | 1 | 2014 | 2021 | 0.020 |
Why?
|
| Self Report | 1 | 2017 | 3707 | 0.020 |
Why?
|
| Anti-HIV Agents | 1 | 2021 | 4492 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2013 | 2138 | 0.020 |
Why?
|
| Gastrointestinal Diseases | 1 | 2013 | 1189 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 2012 | 1534 | 0.020 |
Why?
|
| Transplantation | 1 | 2006 | 218 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2015 | 5201 | 0.020 |
Why?
|
| Adaptation, Psychological | 1 | 2015 | 2628 | 0.020 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2014 | 1162 | 0.010 |
Why?
|
| Administration, Topical | 1 | 2006 | 697 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2023 | 12602 | 0.010 |
Why?
|
| Aortic Valve | 1 | 2014 | 1996 | 0.010 |
Why?
|
| Rural Population | 1 | 2014 | 2267 | 0.010 |
Why?
|
| Hepatitis B | 1 | 2008 | 701 | 0.010 |
Why?
|
| Adiposity | 1 | 2013 | 1851 | 0.010 |
Why?
|
| Patient Education as Topic | 1 | 2013 | 2311 | 0.010 |
Why?
|
| Reoperation | 1 | 2012 | 4292 | 0.010 |
Why?
|
| Cholesterol, HDL | 1 | 2008 | 1817 | 0.010 |
Why?
|
| ROC Curve | 1 | 2009 | 3568 | 0.010 |
Why?
|
| Stents | 1 | 2013 | 3303 | 0.010 |
Why?
|
| Pregnancy | 1 | 2023 | 29725 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 2013 | 4437 | 0.010 |
Why?
|
| Catheterization | 1 | 2006 | 1432 | 0.010 |
Why?
|
| Prednisone | 1 | 2005 | 1566 | 0.010 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2013 | 3967 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2014 | 20484 | 0.010 |
Why?
|
| Hepatitis C | 1 | 2008 | 1578 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2020 | 17766 | 0.010 |
Why?
|
| Equipment Design | 1 | 2006 | 3520 | 0.010 |
Why?
|
| Aging | 1 | 2016 | 8641 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2014 | 36247 | 0.010 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2005 | 1799 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2013 | 26168 | 0.010 |
Why?
|